Checks smell ability in people with glioblastoma brain tumors
Tests smell function in adults with glioblastoma and compares results with survival.
Plain-language title generated from the registry record
Registry title: Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study
Key facts
- Where
- Essen and Münster, GermanySee the 2 sites
Where in Germany
- University Hospital Essen, Department of Neurology, Division of Clinical Neuro-OncologyEssen, GermanyTaking people
- Department of NeurosurgeryMünster, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sied Kebir
- Trial code
- NCT06954636
- Record updated
- 24 August 2026
- Original description
The study aims to investigate the prognostic significance of olfactory function in patients with glioblastoma. We are examining olfactory function at various points during therapy and correlating the results with survival data. In addition, neurocognitive tests will be carried out to correlate the results of olfactory function with the patient's cognitive abilities. Investigations into the quality of life and psychological condition of the patients are also performed. In addition to the cohort of glioblastoma patients, there is a control cohort without tumor disease in which the olfactory testing is also carried out in order to have a comparison.Read full original descriptionShow less
Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational Study
The study aims to investigate the prognostic significance of olfactory function in patients with glioblastoma. We are examining olfactory function at various points during therapy and correlating the results with survival data. In addition, neurocognitive tests will be carried out to correlate the results of olfactory function with the patient's cognitive abilities. Investigations into the quality of life and psychological condition of the patients are also performed. In addition to the cohort of glioblastoma patients, there is a control cohort without tumor disease in which the olfactory testing is also carried out in order to have a comparison.
Inclusion: At least 18 years of age; Newly-diagnosed glioblastoma (IDH wild-type); Never received prior chemotherapy; Never received radiotherapy to the head or neck before; KPS ≥ 70; No history of severe head or brain trauma requiring ICU admission or classified as Glasgow Coma Scale grade 3; No respiratory infection at the time of inclusion; No significant aphasia.
Exclusion: Presence of Neurodegenerative diseases (e.g. Parkinson's disease, Alzheimer's disease, Huntington's disease, Korsakoff's syndrome, Pick's disease, Shy-Drager syndrome); History of invasive tumors or surgery in the head or neck area, except for surgeries for non-invasive skin tumors (e.g. basal cell carcinomas); Permanent olfactory impairment following infections (e.g., influenza, coronavirus); Conditions that, in the examiner's judgment, could interfere with the participant's study compliance (e.g., schizophrenia); Language barriers likely to interfere with participation or comprehension of study procedures.